Table 4 Subgroup multivariate analysis of the association between ACS treatment and adverse offspring outcomes between the HDP-SGA and HDP-non-SGA groups.
HDP-SGA: | HDP-non-SGA: | ||
|---|---|---|---|
ACS vs No-ACS | ACS vs No-ACS | interaction | |
aOR (95% CI) | aOR (95% CI) | p-value | |
Short-term outcomes | |||
In-hospital death | 0.48 (0.31–0.73) | 0.80 (0.43–1.50) | 0.43 |
Respiratory distress syndrome | 0.89 (0.74–1.07) | 0.79 (0.64–0.97) | 0.39 |
Chronic lung disease | 1.37 (1.12–1.68) | 1.33 (1.04–1.69) | 0.93 |
Intraventricular haemorrhage (III or IV) | 0.81 (0.48–1.37) | 0.71 (0.39–1.27) | 0.54 |
Periventricular leukomalacia | 1.06 (0.63–1.76) | 1.18 (0.69–2.05) | 0.88 |
Sepsis | 0.68 (0.50–0.91) | 1.06 (0.71–1.57) | 0.08 |
Necrotizing enterocolitis | 0.67 (0.37–1.24) | 0.55 (0.25–1.19) | 0.73 |
Composite adverse outcomes | 0.67 (0.49–0.91) | 0.90 (0.62–1.30) | 0.49 |
Long-term outcomes | |||
Death after NICU discharge | 1.30 (0.38–4.44) | 1.97 (0.50–7.78) | 0.99 |
Home oxygen therapy/home respiratory therapy | 1.29 (0.49–3.43) | 0.43 (0.14–1.29) | 0.1 |
Visually impairment | 0.91 (0.50–1.67) | 1.60 (0.81–3.17) | 0.33 |
Hearing impairment | 0.33 (0.09–1.18) | 2.00 (0.46–8.72) | 0.22 |
Cerebral palsy | 1.15 (0.65–2.04) | 1.08 (0.58–2.01) | 0.73 |
Developmental quotient <70 | 0.76 (0.50–1.14) | 1.25 (0.75–2.10) | 0.15 |
Developmental quotient <85 | 1.17 (0.86–1.60) | 1.11 (0.79–1.57) | 0.62 |
Composite adverse outcomes | 0.85 (0.62–1.17) | 1.18 (0.80–1.74) | 0.3 |
